Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype

Peter Solar, Laurie Feldman, Jee Yeong Jeong, Jacqueline R. Busingye, Arthur J. Sytkowski

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho-Erk1/2 and increased paclitaxel resistance. This phenotypic effect was specific for paclitaxel, since no change in cisplatin or carboplatin sensitivity was observed. In addition, the change in phenotype was stable, even after the removal of Epo. Measurement of mono- and oligonucleosome formation revealed that long-term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested. Western blot analyses revealed that the long-term Epo treated cells had significantly reduced expression of apoptosis-related proteins Bcl-2 and Bcl-10. These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalInternational Journal of Cancer
Volume122
Issue number2
DOIs
StatePublished - Jan 15 2008
Externally publishedYes

Fingerprint

Erythropoietin
Paclitaxel
Ovarian Neoplasms
Phenotype
Therapeutics
Hematinics
Apoptosis
Erythropoietin Receptors
Erythropoiesis
Carboplatin
Cisplatin
Anemia
Glycoproteins
Western Blotting
Hormones
Neoplasms
Proteins

Keywords

  • Apoptosis
  • Chemoresistance
  • Erythropoietin
  • Ovarian cancer
  • Paclitaxel
  • Signaling

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. / Solar, Peter; Feldman, Laurie; Jeong, Jee Yeong; Busingye, Jacqueline R.; Sytkowski, Arthur J.

In: International Journal of Cancer, Vol. 122, No. 2, 15.01.2008, p. 281-288.

Research output: Contribution to journalArticle

Solar, Peter ; Feldman, Laurie ; Jeong, Jee Yeong ; Busingye, Jacqueline R. ; Sytkowski, Arthur J. / Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. In: International Journal of Cancer. 2008 ; Vol. 122, No. 2. pp. 281-288.
@article{4f9b369557b2428a9b283fd16cdf5ea4,
title = "Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype",
abstract = "Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho-Erk1/2 and increased paclitaxel resistance. This phenotypic effect was specific for paclitaxel, since no change in cisplatin or carboplatin sensitivity was observed. In addition, the change in phenotype was stable, even after the removal of Epo. Measurement of mono- and oligonucleosome formation revealed that long-term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested. Western blot analyses revealed that the long-term Epo treated cells had significantly reduced expression of apoptosis-related proteins Bcl-2 and Bcl-10. These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients.",
keywords = "Apoptosis, Chemoresistance, Erythropoietin, Ovarian cancer, Paclitaxel, Signaling",
author = "Peter Solar and Laurie Feldman and Jeong, {Jee Yeong} and Busingye, {Jacqueline R.} and Sytkowski, {Arthur J.}",
year = "2008",
month = "1",
day = "15",
doi = "10.1002/ijc.23071",
language = "English (US)",
volume = "122",
pages = "281--288",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype

AU - Solar, Peter

AU - Feldman, Laurie

AU - Jeong, Jee Yeong

AU - Busingye, Jacqueline R.

AU - Sytkowski, Arthur J.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho-Erk1/2 and increased paclitaxel resistance. This phenotypic effect was specific for paclitaxel, since no change in cisplatin or carboplatin sensitivity was observed. In addition, the change in phenotype was stable, even after the removal of Epo. Measurement of mono- and oligonucleosome formation revealed that long-term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested. Western blot analyses revealed that the long-term Epo treated cells had significantly reduced expression of apoptosis-related proteins Bcl-2 and Bcl-10. These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients.

AB - Erythropoietin (Epo), a glycoprotein hormone that is the principal regulator of erythropoiesis, is known to act also on nonhematopoietic cell types. Epo receptors have been reported on several normal and neoplastic human cells and tissues, including ovarian cancer cells. We found that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling, evidenced by increased peak levels of phospho-Erk1/2 and increased paclitaxel resistance. This phenotypic effect was specific for paclitaxel, since no change in cisplatin or carboplatin sensitivity was observed. In addition, the change in phenotype was stable, even after the removal of Epo. Measurement of mono- and oligonucleosome formation revealed that long-term Epo treated A2780 cells exhibited markedly less apoptosis than nonerythropoietin treated cells at essentially all concentrations of paclitaxel tested. Western blot analyses revealed that the long-term Epo treated cells had significantly reduced expression of apoptosis-related proteins Bcl-2 and Bcl-10. These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients.

KW - Apoptosis

KW - Chemoresistance

KW - Erythropoietin

KW - Ovarian cancer

KW - Paclitaxel

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=36849026097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849026097&partnerID=8YFLogxK

U2 - 10.1002/ijc.23071

DO - 10.1002/ijc.23071

M3 - Article

VL - 122

SP - 281

EP - 288

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -